Search Result for Drug name

Abciximab

CARDIOVASCULAR SYSTEM

ANTIPLATELETS - [ CARDIOVASCULAR SYSTEM ]

Abciximab is an antiplatelet drug which inhibit the final common pathway of platelet aggregation by blocking fibrinogen and von Willebrand factor (vWF) from binding to activated glycoprotein (GP) IIb/IIIa(1)

As an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications: In patients undergoing percutaneous coronary intervention In patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours (2)

Active internal bleeding Recent (within six weeks) gastrointestinal (GI) or genitourinary (GU) bleeding of clinical significance. History of cerebrovascular accident (CVA) within two years, or CVA with a significant residual neurological deficit Bleeding diathesis Administration of oral anticoagulants within seven days unless prothrombin time is < 1.2 times control Thrombocytopenia (< 100,000 cells/pL) Recent (within six weeks) major surgery or trauma Intracranial neoplasm, arteriovenous malformation, or aneurysm Severe uncontrolled hypertension Presumed or documented history of vasculitis Use of intravenous dextran before percutaneous coronary intervention, or intent to use it during an intervention (2)

Bleeding Intracranial hemorrhage and stroke Thrombocytopenia Hypotension, bradycardia Nausea, vomiting, abdominal pain Headache, back pain and chest pain (2)

Heparin, other anticoagulants, thrombolytics, and antiplatelet agents: Increased risk of bleeding Patients with high anti-human chimeric antibody (HACA) titres may have allergic or hypersensitivity reactions when treated with other diagnostic or therapeutic monoclonal antibodies. (2)

Abciximab should be given to a pregnant woman only if clearly needed Caution should be exercised when Abciximab is administered to a nursing woman. Safety and effectiveness in pediatric patients have not been studied (2)

0.25 mg/kg bolus followed by infusion of 0.125 µg/kg per min (maximum 10 µg/min) for 12 to 24 h. (3)

1.Weitz JZ. Blood coagulation and anticoagulants, fibrinolytics and antiplatelet drugs. In: Brunton L, Chabner B, Knollmann B eds. Goodman & Gilman’s The Pharmacological basis of Therapeutics. 12th ed. China: McGraw Hill; 2011. P849-77 2. Reopro [Internet]. [cited 2013 September 13]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/1997/abcicen110597-lab.pdf 3. National Formulary of India. 4 th ed. Government of India, Ministry of Health and Family Welfare. India: Indian Pharmacopoeia Commission; 2011.